Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
In-licensing

NCEs, new patented formulations and products

Respiratory; women's care; dermatology; pain relief; GI

Full description

Zambon's Corporate Licensing Department is always actively looking for projects/products, also through synergistic collaboration, to implement the company's pipeline as well as partners to fully exploit Zambon project portfolio. Zambon's current strategy is to develop a portfolio of products that extends beyond an exclusive focus on ethical drugs, with an integrated product line ranging from classical ethical drugs to supplements and self-medication products, providing a complete "disease management" system. Main target diseases are all these illnesses that are primarily diagnosed by GPs or chronic pathologies that are followed by the GPs.

Development status

Phase I

Type of business relationship sought

Zambon's Corporate Licensing is looking for NCEs, new patented formulations and products for the treatment of: * Respiratory * Woman's Care * Dermatology * Pain relief * GastroIntestinal Business relationship sought * In-licensing * Co-development, co-commercialisation, partnerships
Partnering consultation free of charge
Need competitive intelligence information
MipTec
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us